Keywords
Acarbose tablets
Elderly diabetes mellitus
Clinical effect
Glycosylated hemoglobin
Submitted : 2023-02-26
Accepted : 2023-03-13
Published : 2023-03-28
Abstract
Objective: To analyze the clinical effects of insulin glargine and acarbose tablets in the treatment of diabetes mellitus in the elderly and the analysis of glycosylated hemoglobin. Methods: Patients (80 cases) from Taizhou City Hospital of Traditional Chinese and Western Medicine (January 2021–December 2022) were randomly divided into two groups (40 cases/group). Patients in the control group were treated with acarbose tablets, whereas those in the observation group were treated with insulin glargine and acarbose tablets. The clinical effects were compared. Results: The difference in blood glucose level and quality of life score between the two groups before treatment was insignificant (P > 0.05). The total effective rate (97.5%) of the observation group was significantly higher than that of the control group (85.0%); the blood sugar indices of the observation group were significantly lower than those of the control group; and the observation group scored higher in the quality-of-life scale than the control group (P < 0.05). Conclusion: Diabetes in elderly is characterized by repeated attacks. The elderly often suffers from chronic diseases, such as cardiovascular disease and respiratory system disease, making it is challenging to achieve the desired effect in treatment. Therefore, it is necessary to explore new treatment methods for the management of diabetes in the elderly. Insulin glargine is a new type of insulin analog, which can last for 24 hours, effectively controlling patients’ blood sugar level. According to research, insulin glargine can effectively regulate the blood sugar level of diabetic patients for an extended period of time, significantly lower the fasting blood sugar, and reduce the complications caused by hypoglycemia. Acarbose tablet, on the other hand, is an alpha-glucosidase inhibitor, which prevents the breakdown of starch into sugar, thereby reducing postprandial blood sugar levels. For diabetic patients, especially those whose staple food is starch, acarbose is a suitable drug.
References
Hu X, 2021, Analysis of the Effect of Insulin Glargine Combined with Acarbose on Elderly Diabetes. Chinese Medicine and Clinic, 21(11): 1944–1946.
Jiao Y, 2020, Analysis of the Curative Effect of Insulin Glargine Combined with Acarbose Tablets in the Treatment of Senile Diabetes. Chongqing Medicine, 49(S02): 177–179.
Lin H, Yu L, Wang L, et al., 2022, Correlation Analysis of Serum Glycated Hemoglobin and Total Bilirubin Levels with Early Kidney Damage in Elderly Patients with Type 2 Diabetes Mellitus. Gerontology and Health Care, 28(1): 158–162.
Tian M, 2021, Clinical Efficacy and Safety Analysis of Treatment with Liraglutide and Insulin Glargine in Patients with Type 2 Diabetes Who Are Poorly Controlled by Metformin Alone. China Practical Medicine, 16(30): 122–124.
Shi Y, Ding Y, Ding L, 2021, Effect of Needle-Free Injection of Insulin Glargine on Glycemic Control of Type 2 Diabetes and Islet ?-Cell Function. Chongqing Medicine, 50(22): 3883–3886 + 3891.
Lin H, Yu L, Wang L, et al., 2022, Correlation Analysis of Serum Glycosylated Hemoglobin and Total Bilirubin Levels with Early Kidney Damage in Elderly Patients with Type 2 Diabetes Mellitus. Geriatric Medicine and Health Care, 28(1): 158–162.
Fang F, Wang N, Liu X, et al., 2022, The Role of Insulin Therapy in Long-Term Blood Sugar Control and Glycated Hemoglobin Variability in Elderly Patients with Type 2 Diabetes. Chinese Drug Application and Monitoring, 19(5): 281–284.
Wu F, Wang L, 2022, Clinical Effects of Canagliflozin Tablets and Acarbose Capsules Combined with Metformin in the Treatment of Diabetes Mellitus. Chinese Journal of Health Inspection, 32(17): 2119–2122.
Li L, 2021, Comparative Analysis of the Effects of Insulin Glargine and Premixed Insulin Combined with Oral Hypoglycemic Drugs in the Treatment of Type 2 Diabetes. Frontiers of Medicine, 11(4): 93–94 + 114.
Wen H, Yang D, 2022, Clinical Efficacy and Safety Evaluation of Insulin Glargine Combined with Acarbose Tablets in the Treatment of Elderly Patients with Diabetes Mellitus. Chinese Modern Drug Application, 16(7): 112–114.
Zhang Y, 2021, The Effect and Safety of Insulin Glargine Combined with Acarbose Tablets in the Treatment of Senile Diabetes Mellitus. Journal of Clinical Rational Drug Use, 14(2): 87–88.
Wang X, 2022, Clinical Effect Analysis of Insulin Glargine, Glimepiride, and Acarbose Tablets Combined in the Treatment of Type 2 Diabetic Patients with Secondary Sulfonylurea Failure. Diabetes New World, 25(6): 88–90 + 94.
Yue C, 2021, Clinical Effect Analysis of Insulin Glargine, Glimepiride, and Acarbose Tablets Combined in the Treatment of Type 2 Diabetic Patients with Secondary Sulfonylurea Failure. Chinese Prescription Drugs, 19(8): 120–122.
Zhang J, Li A, Jiang Y, et al., 2020, Cost and Effect Analysis of the Standardized Comprehensive Management Model of Mobile Medical Care for Type 2 Diabetes Initial Insulin Glargine Patients. Chinese Journal of Diabetes, 28(10): 752–756.
Niu Y, Wang S, Hao J, et al., 2021, Study on the Correlation Between Glycated Hemoglobin and Cystatin C in Patients with Type 2 Diabetes After Liraglutide Treatment. Hainan Medicine, 32(11): 1377–1379.